Gyre Therapeutics, Inc.
NASDAQ:GYREBiotechnology
+$0.00 today
- Market cap
- $475.02M
- Beta
- 4.92
- P/E (TTM)
- -88.3
- EPS (TTM)
- -$0.07
Volume 0.47M
Average 0.09M
Returns on capital
Gyre Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
4.7%
avg 0.1%
ROIC
5.3%
avg -51.0%
ROA
3.0%
avg -43.7%
Analysis
ROIC is currently the strongest return metric at 5.3% versus its period average of -51.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Weiguo Ye | Chief Operating Officer | USD 563.41K | 48 | 700.00K | 0.72% |
Ruoyu Chen | Chief Information Officer | USD 285.58K | 55 | 50.00K | 0.05% |
Ying Luo | CEO, President & Director | USD 85K | 61 | 120.00K | 0.12% |
Thomas W. Eastling | Chief Financial Officer | USD 50K | 67 | — | — |
Yue Xiong | Chief Scientific Officer & Director | — | — | 2.38M | 2.45% |
Jing Liu | Senior Vice President of Platform Chemistry | — | — | — | — |
Mark Marino | Senior Vice President of Clinical Development | — | — | — | — |
Jialiang Wang | Executive VP & GM | — | — | — | — |
Joshua Bergmann | General Counsel & Corporate Secretary | — | — | — | — |
Seth Goldblum | Senior Vice President of Corporate Development | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jun 18, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
17
$895,064.76
Net Transaction Value
−$895,064.76
Net selling
Most Active
Ye Weiguo
15 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jun 18, 26Jun 18, 2026 | Ye Weiguo Direct | Sell | $19.1K$19,050.00 |
| Jun 11, 26Jun 11, 2026 | Ye Weiguo Direct | Sell | $17.3K$17,276.00 |
| Jun 10, 26Jun 10, 2026 | Ye Weiguo Direct | Sell | $31.2K$31,200.00 |
| Jun 10, 26Jun 10, 2026 | Ye Weiguo Direct | Sell | $39.9K$39,855.78 |
| Jun 9, 26Jun 9, 2026 | Ye Weiguo Direct | Sell | $89K$89,030.00 |
| Jun 9, 26Jun 9, 2026 | Ye Weiguo Direct | Sell | $18.5K$18,450.00 |
| Jun 5, 26Jun 5, 2026 | Ye Weiguo Direct | Sell | $98.6K$98,566.40 |
| Jun 4, 26Jun 4, 2026 | Ye Weiguo Direct | Sell | $120K$119,994.75 |
| May 26, 26May 26, 2026 | Ye Weiguo Direct | Sell | $24.4K$24,400.40 |
| May 22, 26May 22, 2026 | Ye Weiguo Direct | Sell | $21.3K$21,280.00 |
1–10 of 17
Summary
Insiders reported 0 buys worth $0.00 and 17 sells worth $895,064.76 over the last 12 months. That adds up to net selling of $895,064.76. Ye Weiguo was the most active insider with 15 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -9.1% | +76.0% (5yr)1 analysts |
| Revenue | N/A | N/A | +4.5% | +22.6% (5yr)1 analysts |
| Net Income | N/A | N/A | +29.7% | +50.8% (5yr)1 analysts |
| EBIT | N/A | N/A | +7.7% | +40.5% (5yr)1 analysts |
Analysis
Recent growth has been strongest in Net Income at +29.7% over three years. Forward estimates point to EPS at +76.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Gyre Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about GYRE's management, answered from reported figures.
Who manages GYRE?
Gyre Therapeutics, Inc. (GYRE) lists 10 active executives. The top listed executive is Yue Xiong, Chief Scientific Officer & Director.
Are GYRE insiders buying or selling?
Recent insider activity shows net buying of $12.31M.
Continue the stock analysis
Jump to another research area for this company.